Filing Flows › BioCorRx (BICX) › Q1 2025
BioCorRx (BICX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
BioCorRx (BICX) reported revenue of $135K for the first quarter 2025 (Q1 2025), up 37-fold from a year earlier. Operating margin was -695.3%, net loss $852K (631.4% of revenue).
BioCorRx, Q1 2025: revenue $135K (37× year over year), operating margin -695.3%, net loss $852K, operating cash flow −$690K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $135K | — | 37× |
| Operating profit | −$938K | — | — |
| Net earnings | −$852K | — | — |
| Operating cash flow | −$690K | — | — |
What changed
Revenue was $135K in Q1 2025, up 3626% year over year.
Operating costs exceeded revenue by $938K, an operating margin of -695.3%. Total costs grew 10% against revenue growth of 3626%. The fastest-growing cost line was Other operating costs (+270%). The quarter ended with a net loss of $852K. Minority interests bore $10K of it: to shareholders the quarter was a loss of $841K.
Operating cash flow was −$690K. Non-cash charges added back $25K of depreciation and amortization and $151K of share-based compensation.
Questions
What was BioCorRx's revenue in the first quarter 2025?
BioCorRx (BICX) reported revenue of $135K for the first quarter 2025 (Q1 2025), up 37-fold from a year earlier.
Was BioCorRx profitable in the first quarter 2025?
Operating loss was $938K (-695.3% of revenue) and net loss $852K.
Source: BioCorRx 10-Q on SEC EDGAR.